Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Fresenius Medical Care AG & Co. KGaA is a global leader in providing dialysis products and services, operating over 4,000 dialysis clinics worldwide, primarily in North America and Europe. The company benefits from a strong integrated business model combining product manufacturing with service provision, which enhances patient care and drives recurring revenue.
Fresenius generates revenue through a combination of providing dialysis treatments and selling related medical equipment. The company has strong pricing power due to its established brand and extensive distribution network, allowing it to maintain margins despite competitive pressures.
Changes in Medicare reimbursement rates for dialysis services
Expansion of dialysis clinics in emerging markets
Innovations in dialysis technology and product offerings
Regulatory changes impacting healthcare reimbursements
Regulatory changes affecting healthcare reimbursements and pricing structures
Technological disruption from new dialysis treatment options
Increased competition from other dialysis service providers and emerging technologies
Potential market share loss to local players in emerging markets
Moderate financial risk due to existing debt levels
Potential pension obligations impacting cash flow
moderate - Demand for dialysis services is relatively inelastic, but overall healthcare spending can be influenced by GDP growth.
Higher interest rates could increase Fresenius's borrowing costs, affecting capital expenditures and potentially slowing down clinic expansion plans.
minimal - The company has a manageable debt level with a debt/equity ratio of 0.83, indicating limited reliance on credit markets.
value - The stock's low price-to-sales and price-to-book ratios suggest potential undervaluation, appealing to value investors.
moderate - The stock has shown historical volatility, with a beta around 1.2, indicating it is somewhat more volatile than the market.